Clinical trials: Chronic Illnesses, Multiple
- Condition Chronic Illnesses, Multiple
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy Participants
A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants
The main purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral AZD6793 in healthy Japanese and Chinese participants.
- Trial name
- NCT06368440
- Testing
- AZD6793
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Hepatitis c
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
- Trial name
- NCT03673696
- Testing
- HEC74647PA Capsule
- Where
- China
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
COPD
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.
The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation and inhalation suspension administered in a single dose in healthy individuals and multiple doses in patients with COPD
- Trial name
- NCT07116915
- Testing
- HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension, Moxifloxacin Hydrochloride Tablets
- Where
- China
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Chronic Obstructive Pulmonary Disease
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects
AZD8871 is a new chemical entity possessing long-acting effect in a single molecule which presents a novel treatment approach to chronic obstructive pulmonary disease [COPD] and potentially also asthma (in combination with an…
- Trial name
- NCT02814656
- Testing
- AZD8871
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy, COPD
A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled AZD9164 following administration of multiple ascending doses in healthy male and female subjects and COPD…
- Trial name
- NCT01016951
- Testing
- AZD9164 Turbuhaler®
- Where
- 2 sites in Sweden
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Hepatitis C
Clinical Pharmacology Study of MP-424
To conduct the following evaluations in Korean healthy male adult volunteers receiving a single and multiple doses of MP-424 tablets: Pharmacokinetics of MP-424 after a single and multiple doses.
- Trial name
- NCT01766167
- Testing
- MP-424
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Disease, Healthy Volunteers
A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD). The kidneys filter extra water and waste out of the blood and make urine.
- Trial name
- NCT05800444
- Testing
- BAY3283142
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease
Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients
There are three elements to this study: Part A: Single dose escalation in healthy subjects. 6 dose levels of QAK423 are planned in healthy volunteers. Part B: Single dose escalation in patients with mild/moderate COPD.
- Trial name
- NCT01197287
- Testing
- QAK423A
- Where
- Germany
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy Participants, Chronic Spontaneous Urticaria
Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria
This is a Phase 1, randomized, double-blind, placebo-controlled, sequential, single- and multiple-ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of intravenous (IV) infusions…
- Trial name
- NCT06072157
- Testing
- AK006-IV, AK006-SC
- Where
- 25 sites in United States, Canada
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Allakos Inc.
Chronic Obstructive Pulmonary Disease
A Study to Assess Safety, Tolerability and Pharmacokinetics of of AZD6553 in Healthy Volunteers and Patients With Chronic Obstructive Pulmonary Disease (COPD)
AZD6553 is a new drug being developed as a possible treatment for patients with chronic obstructive pulmonary disease (COPD). COPD refers to chronic bronchitis and emphysema, a pair of two commonly co-existing diseases of the…
- Trial name
- NCT01068184
- Testing
- AZD6553
- Where
- United Kingdom
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, Enterovirus Infections
First-in-human Clinical Trial Evaluating CUR-N399 in Healthy Volunteers.
The purpose of the trial is to evaluate CUR-N399, a PI4KB inhibitor, in a first-in-human trial to evaluate the safety, tolerability and pharmacokinetics profile of single and multiple ascending doses in healthy adults.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Enterovirus Infections, Rhinovirus
- Trial name
- NCT05016687
- Testing
- CUR-N399
- Where
- Sweden
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Curovir AB
Chronic Hepatitis C
Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)
This is a multi-part study to evaluate the safety, tolerability, and pharmacokinetics (PK) of uprifosbuvir (MK-3682/IDX21437) in healthy participants and in participants infected with Hepatitis C virus (HCV) genotype (GT)1-GT6.
- Trial name
- NCT01974687
- Testing
- Uprifosbuvir, Itraconazole
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy, Hepatitis, Chronic
A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)
The purpose of this study is to evaluate pharmacokinetics and safety data including serious and other adverse events, physical examinations, vital signs, 12-lead electrocardiograms (ECGs) and clinical laboratory results…
- Trial name
- NCT02662712
- Testing
- JNJ-56136379
- Where
- 27 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Janssen Sciences Ireland UC
Chronic Hepatitis B
A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B
This three-part, Phase 1 protocol will be the first clinical study of ABI-H2158. Parts 1 and 2 will be a Phase 1a, dose-ranging assessment of ABI-H2158 in healthy adult volunteers.
- Trial name
- NCT03714152
- Testing
- ABI-H2158
- Where
- 14 sites in United States, Australia and 5 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Chronic Obstructive Pulmonary Disease
Multiple Dose Healthy Volunteer Safety Pharmacokinetics Study
Multiple dose safety and pharmacokinetics in healthy male subjects
- Trial name
- NCT00864786
- Testing
- PF03635659
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers, Hepatitis B, Chronic
A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R
This phase Ib study included two parts in which Part I was to evaluate the safety and bridge for PK among healthy Chinese subjects and Part II were about study among Chinese chronic hepatitis B virus-infected patients.
- Trial name
- NCT05470829
- Testing
- ZM-H1505R
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
Chronic Hepatitis B
A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects
A Randomized Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
- Trial name
- NCT05001022
- Testing
- ALG-020572
- Where
- 3 sites in New Zealand, United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Chronic Hepatitis B
This is a Phase 1 Study in Which Healthy Volunteers and Participants with Chronic HBV Infection Will Receive HT-101 or Placebo and Will Be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity
Phase 1 Study of HT-101 in Healthy Subjects and Patients With Chronic Hepatitis B The trial consisted of two components. Part A involved a single ascending dose study where healthy participants were administered one dose of…
- Trial name
- NCT06746311
- Testing
- HT-101
- Where
- 7 sites in China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Suzhou HepaThera Biotech Co., Ltd.
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects
This is a phase 1, open-label, parallel cohort study to evaluate the PK, safety and tolerability of nebulized ensifentrine following administration of single and multiple doses in healthy Chinese male subjects.
- Trial name
- NCT05758428
- Testing
- Ensifentrine
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Nuance Pharma (shanghai) Co., Ltd
Hepatitis C, Chronic
Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)
The purpose of this study is to evaluate the potential for a PK drug-drug interaction when IDX719, simeprevir, TMC647055 and low-dose ritonavir (RTV) are administered in combination. Safety and tolerability will also be assessed.
- Trial name
- NCT01907724
- Testing
- IDX719, Simeprevir, TMC647055
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC